nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.05.2019 | Basic and Applied Science (I Lewkowich, Section Editor)

Th9 Cells in Allergic Disease

verfasst von: Pornpimon Angkasekwinai

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purposes of Review

Th9 cells are recognized as a novel subset of effector T helper cells that preferentially produce IL-9. Here, we provide a current update on the reports related to the function of Th9 cells in allergic inflammatory diseases.

Recent Findings

The effector Th9 cells differentiating from naïve T helper cells have recently been identified. Because of accumulating findings of Th9 cells in many inflammatory diseases, including allergic diseases, diverse functions of Th9 cells in regulating immune responses have been suggested. Related reports indicate multiple sources of IL-9 besides Th9 cells and their association with the pathogenesis of allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, and food allergy. More recently, elements of the epigenetic landscape involving in the regulation of IL-9 by Th9 cells have been identified to be the potential target for allergic inflammation.

Summary

This review provides the most recent information about Th9 cells and their contribution in airway allergic disease, skin, and food allergy.

Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9(12):1341–6. https://doi.org/10.1038/ni.1659.CrossRefPubMed

Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3(+) T cells and, together with TGF-beta, generates IL-9(+) IL-10(+) Foxp3(−) effector T cells. Nat Immunol. 2008;9(12):1347–55. https://doi.org/10.1038/ni.1677.CrossRefPubMedPubMedCentral

Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, et al. Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest. 2013;123(11):4641–53. https://doi.org/10.1172/JCI69489.CrossRefPubMedPubMedCentral

•• Micosse C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, et al. Human "TH9" cells are a subpopulation of PPAR-gamma(+) TH2 cells. Sci Immunol. 2019;4(31). https://doi.org/10.1126/sciimmunol.aat5943 COMMENT: Study showing that Th9 subset transiently induced during skin inflammation is a subpopulation of Th2 lineage. CrossRef

Clark RA, Schlapbach C. TH9 cells in skin disorders. Semin Immunopathol. 2017;39(1):47–54. https://doi.org/10.1007/s00281-016-0607-8.CrossRefPubMed

Licona-Limon P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limon I, Ishigame H, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity. 2013;39(4):744–57. https://doi.org/10.1016/j.immuni.2013.07.020.CrossRefPubMed

Angkasekwinai P, Srimanote P, Wang YH, Pootong A, Sakolvaree Y, Pattanapanyasat K, et al. Interleukin-25 (IL-25) promotes efficient protective immunity against Trichinella spiralis infection by enhancing the antigen-specific IL-9 response. Infect Immun. 2013;81(10):3731–41. https://doi.org/10.1128/IAI.00646-13.CrossRefPubMedPubMedCentral

Jones CP, Gregory LG, Causton B, Campbell GA, Lloyd CM. Activin a and TGF-beta promote T(H)9 cell-mediated pulmonary allergic pathology. J Allergy Clin Immunol. 2012;129(4):1000–10 e3. https://doi.org/10.1016/j.jaci.2011.12.965.CrossRefPubMedPubMedCentral

Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol. 2010;11(3):250–6. https://doi.org/10.1038/ni.1846.CrossRefPubMedPubMedCentral

10.

Chang HC, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol. 2010;11(6):527–34. https://doi.org/10.1038/ni.1867.CrossRefPubMedPubMedCentral

11.

Vargas TR, Humblin E, Vegran F, Ghiringhelli F, Apetoh L. T(H)9 cells in anti-tumor immunity. Semin Immunopathol. 2017;39(1):39–46. https://doi.org/10.1007/s00281-016-0599-4.CrossRef

12.

Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers. 2015;3(1–2):e983777. https://doi.org/10.4161/21688370.2014.983777.CrossRefPubMedPubMedCentral

13.

Romagnani S. Immunologic influences on allergy and theT(H)1/T(H)2 balance. J Allergy Clin Immunol. 2004;113(3):395–400. https://doi.org/10.1016/j.jaci.2003.11.025.CrossRefPubMed

14.

Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463(7280):540–4. https://doi.org/10.1038/nature08636.CrossRefPubMed

15.

Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A. 2010;107(25):11489–94. https://doi.org/10.1073/pnas.1003988107.CrossRefPubMedPubMedCentral

16.

Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70. https://doi.org/10.1038/nature08900.CrossRefPubMedPubMedCentral

17.

Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425–35. https://doi.org/10.1016/j.immuni.2014.01.011.CrossRefPubMedPubMedCentral

18.

Liu B, Lee JB, Chen CY, Hershey GK, Wang YH. Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia. J Immunol. 2015;194(8):3583–93. https://doi.org/10.4049/jimmunol.1400951.CrossRefPubMedPubMedCentral

19.

Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015;7(301):301ra129. https://doi.org/10.1126/scitranslmed.aab3142.CrossRefPubMed

20.

Sehra S, Yao W, Nguyen ET, Glosson-Byers NL, Akhtar N, Zhou B, et al. TH9 cells are required for tissue mast cell accumulation during allergic inflammation. J Allergy Clin Immunol. 2015;136(2):433–40 e1. https://doi.org/10.1016/j.jaci.2015.01.021.CrossRefPubMedPubMedCentral

21.

Kim BS, Kim IK, Park YJ, Kim YS, Kim YJ, Chang WS, et al. Conversion of Th2 memory cells into Foxp3+ regulatory T cells suppressing Th2-mediated allergic asthma. Proc Natl Acad Sci U S A. 2010;107(19):8742–7. https://doi.org/10.1073/pnas.0911756107.CrossRefPubMedPubMedCentral

22.

Murugaiyan G, Beynon V, Da Cunha AP, Joller N, Weiner HL. IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol. 2012;189(11):5277–83. https://doi.org/10.4049/jimmunol.1200808.CrossRefPubMedPubMedCentral

23.

Anuradha R, George PJ, Hanna LE, Chandrasekaran V, Kumaran P, Nutman TB, et al. IL-4-, TGF-beta-, and IL-1-dependent expansion of parasite antigen-specific Th9 cells is associated with clinical pathology in human lymphatic Filariasis. J Immunol. 2013;191(5):2466–73. https://doi.org/10.4049/jimmunol.1300911.CrossRefPubMedPubMedCentral

24.

Liao W, Spolski R, Li P, Du N, West EE, Ren M, et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A. 2014;111(9):3508–13. https://doi.org/10.1073/pnas.1301138111.CrossRefPubMedPubMedCentral

25.

Yao WG, Zhang YL, Jabeen R, Nguyen ET, Wilkes DS, Tepper RS, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 2013;38(2):360–72. https://doi.org/10.1016/j.immuni.2013.01.007.CrossRefPubMedPubMedCentral

26.

Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol. 2010;88(6):624–31. https://doi.org/10.1038/icb.2010.53.CrossRefPubMedPubMedCentral

27.

Xiao X, Balasubramanian S, Liu WT, Chu XF, Wang HB, Taparowsky EJ, et al. OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol. 2012;13(10):981–90. https://doi.org/10.1038/ni.2390.CrossRefPubMedPubMedCentral

28.

Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, et al. Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol. 2013;131(4):1048–57, 57 e1–2. https://doi.org/10.1016/j.jaci.2012.09.027.CrossRefPubMed

29.

Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21(9):1010–7. https://doi.org/10.1038/nm.3922.CrossRefPubMed

30.

Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun. 2015;6:8266. https://doi.org/10.1038/ncomms9266.CrossRefPubMedPubMedCentral

31.

Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al. Notch receptors and Smad3 signaling cooperate in the induction of Interleukin-9-producing T cells. Immunity. 2012;36(4):623–34. https://doi.org/10.1016/j.immuni.2012.01.020.CrossRefPubMedPubMedCentral

32.

Richard AC, Tan CY, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, et al. The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells. J Immunol. 2015;194(8):3567–82. https://doi.org/10.4049/jimmunol.1401220.CrossRefPubMedPubMedCentral

33.

Goswami R, Jabeen R, Yagi R, Pham D, Zhu JF, Goenka S, et al. STAT6-dependent regulation of Th9 development. J Immunol. 2012;188(3):968–75. https://doi.org/10.4049/jimmunol.1102840.CrossRefPubMed

34.

Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010;33(2):192–202. https://doi.org/10.1016/j.immuni.2010.07.014.CrossRefPubMed

35.

Zhu YX, Kang LY, Luo W, Li CC, Yang L, Yang YC. Multiple transcription factors are required for activation of human interleukin 9 gene in T cells. J Biol Chem. 1996;271(26):15815–22.CrossRef

36.

Jash A, Sahoo A, Kim GC, Chae CS, Hwang JS, Kim JE, et al. Nuclear factor of activated T cells 1 (NFAT1)-induced permissive chromatin modification facilitates nuclear factor-kappaB (NF-kappaB)-mediated interleukin-9 (IL-9) transactivation. J Biol Chem. 2012;287(19):15445–57. https://doi.org/10.1074/jbc.M112.340356.CrossRefPubMedPubMedCentral

37.

Tamiya T, Ichiyama K, Kotani H, Fukaya T, Sekiya T, Shichita T, et al. Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. J Immunol. 2013;191(5):2360–71. https://doi.org/10.4049/jimmunol.1301276.CrossRefPubMed

38.

Humblin E, Thibaudin M, Chalmin F, Derangere V, Limagne E, Richard C, et al. IRF8-dependent molecular complexes control the Th9 transcriptional program. Nat Commun. 2017;8(1):2085. https://doi.org/10.1038/s41467-017-01070-w.CrossRefPubMedPubMedCentral

39.

Malik S, Sadhu S, Elesela S, Pandey RP, Chawla AS, Sharma D, et al. Transcription factor Foxo1 is essential for IL-9 induction in T helper cells. Nat Commun. 2017;8(1):815. https://doi.org/10.1038/s41467-017-00674-6.CrossRefPubMedPubMedCentral

40.

•• Xiao X, Fan Y, Li J, Zhang X, Lou X, Dou Y, et al. Guidance of super-enhancers in regulation of IL-9 induction and airway inflammation. J Exp Med. 2018;215(2):559–74. https://doi.org/10.1084/jem.20170928 COMMENT: Study identifying the elements for the epigenetic landscape regulating IL-9 expression by Th9 cells that could be another target for allergic airway inflammation. CrossRefPubMedPubMedCentral

41.

•• Koh B, Abdul Qayum A, Srivastava R, Fu Y, Ulrich BJ, Janga SC, et al. A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun. 2018;9(1):4803. https://doi.org/10.1038/s41467-018-07202-0 COMMENT: Study identifying a conserved IL-9 regulatory element, CNS-25 as enhancer for IL-9 expression in multiple cell types, including Th9 cells. CrossRefPubMedPubMedCentral

42.

Chen CY, Lee JB, Liu B, Ohta S, Wang PY, Kartashov AV, et al. Induction of Interleukin-9-producing mucosal mast cells promotes susceptibility to IgE-mediated experimental food allergy. Immunity. 2015;43(4):788–802. https://doi.org/10.1016/j.immuni.2015.08.020.CrossRefPubMedPubMedCentral

43.

Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med. 2013;210(13):2951–65. https://doi.org/10.1084/jem.20130071.CrossRefPubMedPubMedCentral

44.

Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017;23(8):938–44. https://doi.org/10.1038/nm.4373.CrossRefPubMedPubMedCentral

45.

Visekruna A, Ritter J, Scholz T, Campos L, Guralnik A, Poncette L, et al. Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation. Eur J Immunol. 2013;43(3):606–18. https://doi.org/10.1002/eji.201242825.CrossRefPubMed

46.

Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009;206(8):1653–60. https://doi.org/10.1084/jem.20090246.CrossRefPubMedPubMedCentral

47.

Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;106(31):12885–90. https://doi.org/10.1073/pnas.0812530106.CrossRefPubMedPubMedCentral

48.

Doull IJ, Lawrence S, Watson M, Begishvili T, Beasley RW, Lampe F, et al. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med. 1996;153(4 Pt 1):1280–4. https://doi.org/10.1164/ajrccm.153.4.8616554.CrossRefPubMed

49.

Ulbrecht M, Eisenhut T, Bonisch J, Kruse R, Wjst M, Heinrich J, et al. High serum IgE concentrations: association with HLA-DR and markers on chromosome 5q31 and chromosome 11q13. J Allergy Clin Immunol. 1997;99(6 Pt 1):828–36.CrossRef

50.

Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, et al. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol. 1999;29(7):2130–9. https://doi.org/10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S.CrossRefPubMed

51.

Longphre M, Li D, Gallup M, Drori E, Ordonez CL, Redman T, et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest. 1999;104(10):1375–82. https://doi.org/10.1172/JCI6097.CrossRefPubMedPubMedCentral

52.

Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest. 2002;109(1):29–39. https://doi.org/10.1172/JCI13696.CrossRefPubMedPubMedCentral

53.

Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, McKenzie NA. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity. 2000;13(4):573–83.CrossRef

54.

Kung TT, Luo B, Crawley Y, Garlisi CG, Devito K, Minnicozzi M, et al. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol. 2001;25(5):600–5. https://doi.org/10.1165/ajrcmb.25.5.4533.CrossRefPubMed

55.

Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166(3):409–16. https://doi.org/10.1164/rccm.2105079.CrossRefPubMed

56.

Angkasekwinai P. Allergic inflammation and atopic disease: role of Th9 cells. Methods Mol Biol. 2017;1585:189–99. https://doi.org/10.1007/978-1-4939-6877-0_15.CrossRefPubMed

57.

Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol. 2011;12(11):1071–7. https://doi.org/10.1038/ni.2133.CrossRefPubMedPubMedCentral

58.

•• Moretti S, Renga G, Oikonomou V, Galosi C, Pariano M, Iannitti RG, et al. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat Commun. 2017;8:14017. https://doi.org/10.1038/ncomms14017 COMMENT: Study indicating the collaborative network of Th9, ILC2 and mast cells in amplifying lung inflammation. CrossRefPubMedPubMedCentral

59.

Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000;105(1 Pt 1):108–15.CrossRef

60.

Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol. 2003;111(6):1319–27.CrossRef

61.

Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-kit(+) mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol. 2005;116(1):73–9. https://doi.org/10.1016/j.jaci.2005.03.011.CrossRefPubMed

62.

Devos S, Cormont F, Vrtala S, Hooghe-Peters E, Pirson F, Van Snick J. Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. Clin Exp Allergy. 2006;36(2):174–82. https://doi.org/10.1111/j.1365-2222.2006.02422.x.CrossRefPubMed

63.

Umezu-Goto M, Kajiyama Y, Kobayashi N, Kaminuma O, Suko M, Mori A. IL-9 production by peripheral blood mononuclear cells of atopic asthmatics. Int Arch Allergy Immunol. 2007;143:76–9. https://doi.org/10.1159/000101410.CrossRefPubMed

64.

Yao WG, Tepper RS, Kaplan MH. Predisposition to the development of IL-9-secreting T cells in atopic infants. J Allergy Clin Immunol. 2011;128(6):1357–60. https://doi.org/10.1016/j.jaci.2011.06.019.CrossRefPubMedPubMedCentral

65.

Iinuma T, Okamoto Y, Yamamoto H, Inamine-Sasaki A, Ohki Y, Sakurai T, et al. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2015;114(4):289–98. https://doi.org/10.1016/j.anai.2015.01.013.CrossRefPubMed

66.

Hoppenot D, Malakauskas K, Lavinskiene S, Bajoriuniene I, Kalinauskaite V, Sakalauskas R. Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients. Medicina-Lithuania. 2015;51(1):10–7. https://doi.org/10.1016/j.medici.2015.01.001.CrossRef

67.

Jia L, Wang Y, Li J, Li S, Zhang Y, Shen J, et al. Detection of IL-9 producing T cells in the PBMCs of allergic asthmatic patients. BMC Immunol. 2017;18(1):38. https://doi.org/10.1186/s12865-017-0220-1.CrossRefPubMedPubMedCentral

68.

Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94. https://doi.org/10.1056/NEJMra074081.CrossRefPubMed

69.

Lowe AJ, Leung DYM, Tang MLK, Su JC, Allen KJ. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–51. https://doi.org/10.1016/j.anai.2017.11.023.CrossRefPubMed

70.

Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9. https://doi.org/10.1056/NEJMoa1314768.CrossRefPubMed

71.

•• Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8 COMMENT: Clinical trial study indicating the effect of targeting Th2 cytokine IL-4 and IL-13 in atopic dermatitis. CrossRefPubMed

72.

Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–49. https://doi.org/10.1016/j.jaci.2016.06.010.CrossRefPubMed

73.

Lin JY, Chen JS, Hsu CJ, Miaw SC, Liu CY, Lee SJ, et al. Epicutaneous sensitization with protein antigen induces Th9 cells. J Invest Dermatol. 2012;132(3 Pt 1):739–41. https://doi.org/10.1038/jid.2011.382.CrossRefPubMed

74.

Namkung JH, Lee JE, Kim E, Park GT, Yang HS, Jang HY, et al. An association between IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in a Korean population. J Dermatol Sci. 2011;62(1):16–21. https://doi.org/10.1016/j.jdermsci.2011.01.007.CrossRefPubMed

75.

Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Vasiadi M, Therianou A, et al. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One. 2012;7(3):e33271. https://doi.org/10.1371/journal.pone.0033271.CrossRefPubMedPubMedCentral

76.

Ciprandi G, De Amici M, Giunta V, Marseglia A, Marseglia G. Serum Interleukin-9 levels are associated with clinical severity in children with atopic dermatitis. Pediatr Dermatol. 2013;30(2):222–5. https://doi.org/10.1111/j.1525-1470.2012.01766.x.CrossRefPubMed

77.

Hamza AM, Omar SS, Abo El-Wafa RA, Elatrash MJ. Expression levels of transcription factor PU.1 and interleukin-9 in atopic dermatitis and their relation to disease severity and eruption types. Int J Dermatol. 2017;56(5):534–9. https://doi.org/10.1111/ijd.13579.CrossRefPubMed

78.

Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–51. https://doi.org/10.1016/j.jaci.2016.07.013.CrossRefPubMed

79.

Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE, et al. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med. 2014;6(219):219ra8. https://doi.org/10.1126/scitranslmed.3007828.CrossRefPubMedPubMedCentral

80.

Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175(1):25–31. https://doi.org/10.1111/cei.12198.CrossRefPubMed

81.

Coulter EM, Jenkinson C, Farrell J, Lavergne SN, Pease C, White A, et al. Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals. J Invest Dermatol. 2010;130(1):161–74. https://doi.org/10.1038/jid.2009.187.CrossRefPubMed

82.

Baeck M, Herman A, de Montjoye L, Hendrickx E, Cheou P, Cochez PM, et al. Increased expression of interleukin-9 in patients with allergic contact dermatitis caused by p-phenylenediamine. Contact Dermatitis. 2018;79(6):346–55. https://doi.org/10.1111/cod.13123.CrossRefPubMed

83.

Liu J, Harberts E, Tammaro A, Girardi N, Filler RB, Fishelevich R, et al. IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis. J Invest Dermatol. 2014;134(7):1903–11. https://doi.org/10.1038/jid.2014.61.CrossRefPubMedPubMedCentral

84.

Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN, et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol. 2011;186(1):83–91. https://doi.org/10.4049/jimmunol.1001183.CrossRefPubMed

85.

Valenta R, Hochwallner H, Linhart B, Pahr S. Food allergies: the basics. Gastroenterology. 2015;148(6):1120–31 e4. https://doi.org/10.1053/j.gastro.2015.02.006.CrossRefPubMedPubMedCentral

86.

Forbes EE, Groschwitz K, Abonia JP, Brandt EB, Cohen E, Blanchard C, et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008;205(4):897–913. https://doi.org/10.1084/jem.20071046.CrossRefPubMedPubMedCentral

87.

Osterfeld H, Ahrens R, Strait R, Finkelman FD, Renauld JC, Hogan SP. Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol. 2010;125(2):469–76 e2. https://doi.org/10.1016/j.jaci.2009.09.054.CrossRefPubMedPubMedCentral

88.

He SH, Liu ZQ, Chen X, Song CH, Zhou LF, Ma WJ, et al. IL-9(+) IL-10(+) T cells link immediate allergic response to late phase reaction. Clin Exp Immunol. 2011;165(1):29–37. https://doi.org/10.1111/j.1365-2249.2011.04394.x.CrossRefPubMedPubMedCentral

89.

Xie J, Lotoski LC, Chooniedass R, Su RC, Simons FE, Liem J, et al. Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans. PLoS One. 2012;7(10):e45377. https://doi.org/10.1371/journal.pone.0045377.CrossRefPubMedPubMedCentral

90.

Brough HA, Cousins DJ, Munteanu A, Wong YF, Sudra A, Makinson K, et al. IL-9 is a key component of memory TH cell peanut-specific responses from children with peanut allergy. J Allergy Clin Immunol. 2014;134(6):1329–38 e10. https://doi.org/10.1016/j.jaci.2014.06.032.CrossRefPubMed

91.

Shik D, Tomar S, Lee JB, Chen CY, Smith A, Wang YH. IL-9-producing cells in the development of IgE-mediated food allergy. Semin Immunopathol. 2017;39(1):69–77. https://doi.org/10.1007/s00281-016-0605-x.CrossRefPubMed

92.

Antoniu SA. MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther. 2010;12(2):233–9.PubMed

93.

Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011;11:14. https://doi.org/10.1186/1471-2466-11-14.CrossRefPubMedPubMedCentral

94.

Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res. 2013;14:93. https://doi.org/10.1186/1465-9921-14-93.CrossRefPubMedPubMedCentral

95.

Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European academy of allergy and clinical immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–58. https://doi.org/10.1016/j.jaci.2016.03.010.CrossRefPubMed

96.

•• Schwartz DM, Farley TK, Richoz N, Yao C, Shih HY, Petermann F, et al. Retinoic Acid Receptor Alpha Represses a Th9 Transcriptional and Epigenomic Program to Reduce Allergic Pathology. Immunity. 2019;50(1):106–20 e10. https://doi.org/10.1016/j.immuni.2018.12.014 COMMENT: Study indicating the effect of retinoic acid on transcriptome of Th9 cells and repressing Th9 epigenome can control allergic lung pathology. CrossRef

97.

Lloyd CM, Harker JA. Epigenetic control of Interleukin-9 in asthma. N Engl J Med. 2018;379(1):87–9. https://doi.org/10.1056/NEJMcibr1803610.CrossRefPubMed

98.

McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2018;199:433–45. https://doi.org/10.1164/rccm.201810-1944CI.CrossRef

Titel: Th9 Cells in Allergic Disease
verfasst von: Pornpimon Angkasekwinai
Publikationsdatum: 01.05.2019
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 5/2019
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-019-0860-8

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Th9 Cells in Allergic Disease

Abstract

Purposes of Review

Recent Findings

Summary

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purposes of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Evaluating Penicillin Allergies Without Skin Testing

Microbial Adjuncts for Food Allergen Immunotherapy

Contributions of Innate Lymphoid Cells in Chronic Rhinosinusitis

Exosomes in Allergic Airway Diseases

Chlorhexidine Allergy: On the Rise and Often Overlooked

Osteitis in Chronic Rhinosinusitis

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO